AIMS: The Occluded Artery Trial (OAT) (n = 2201) showed no benefit for routine percutaneous intervention (PCI) (n = 1101) over medical therapy (MED) (n = 1100) on the combined endpoint of death, myocardial infarction (MI), and class IV heart failure (congestive heart failure) in stable post-MI patients with late occluded infarct-related arteries (IRAs). We evaluated the potential for selective benefit with PCI over MED for patients enrolled early in OAT. METHODS AND RESULTS: We explored outcomes with PCI over MED in patients randomized to the </=3 calendar days and </=7 calendar days post-MI time windows. Earlier, times to randomization in OAT were associated with higher rates of the combined endpoint (adjusted HR 1.04/day: 99% CI 1.01-1.06; P < 0.001). The 48-month event rates for </=3 days, </=7 days post-MI enrolled patients were similar for PCI vs. MED for the combined and individual endpoints. There was no interaction between time to randomization defined as a continuous (P = 0.55) or categorical variable with a cut-point of 3 days (P = 0.98) or 7 days (P = 0.64) post-MI and treatment effect. CONCLUSION: Consistent with overall OAT findings, patients enrolled in the </=3 day and </=7 day post-MI time windows derived no benefit with PCI over MED with no interaction between time to randomization and treatment effect. Our findings do not support routine PCI of the occluded IRA in trial-eligible patients even in the earliest 24-72 h time window.
RCT Entities:
AIMS: The Occluded Artery Trial (OAT) (n = 2201) showed no benefit for routine percutaneous intervention (PCI) (n = 1101) over medical therapy (MED) (n = 1100) on the combined endpoint of death, myocardial infarction (MI), and class IV heart failure (congestive heart failure) in stable post-MI patients with late occluded infarct-related arteries (IRAs). We evaluated the potential for selective benefit with PCI over MED for patients enrolled early in OAT. METHODS AND RESULTS: We explored outcomes with PCI over MED in patients randomized to the </=3 calendar days and </=7 calendar days post-MI time windows. Earlier, times to randomization in OAT were associated with higher rates of the combined endpoint (adjusted HR 1.04/day: 99% CI 1.01-1.06; P < 0.001). The 48-month event rates for </=3 days, </=7 days post-MI enrolled patients were similar for PCI vs. MED for the combined and individual endpoints. There was no interaction between time to randomization defined as a continuous (P = 0.55) or categorical variable with a cut-point of 3 days (P = 0.98) or 7 days (P = 0.64) post-MI and treatment effect. CONCLUSION: Consistent with overall OAT findings, patients enrolled in the </=3 day and </=7 day post-MI time windows derived no benefit with PCI over MED with no interaction between time to randomization and treatment effect. Our findings do not support routine PCI of the occluded IRA in trial-eligible patients even in the earliest 24-72 h time window.
Authors: Kim A Eagle; Shaun G Goodman; Alvaro Avezum; Andrzej Budaj; Cynthia M Sullivan; José López-Sendón Journal: Lancet Date: 2002-02-02 Impact factor: 79.321
Authors: Yaron Elad; William J French; David M Shavelle; Lori S Parsons; Mark J Sada; Nathan R Every Journal: J Am Coll Cardiol Date: 2002-03-06 Impact factor: 24.094
Authors: R Zahn; R Schiele; S Schneider; A K Gitt; H Wienbergen; K Seidl; C Bossaller; G F Hauf; M Gottwik; E Altmann; W Rosahl; J Senges Journal: J Invasive Cardiol Date: 2001-05 Impact factor: 2.022
Authors: James E Udelson; Camille A Pearte; Carey D Kimmelstiel; Mariusz Kruk; Joseph A Kufera; Sandra A Forman; Anna Teresinska; Bartosz Bychowiec; Jose Antonio Marin-Neto; Thomas Höchtl; Eric A Cohen; Paulo Caramori; Benita Busz-Papiez; Christopher Adlbrecht; Zygmunt P Sadowski; Witold Ruzyllo; Debra J Kinan; Gervasio A Lamas; Judith S Hochman Journal: Am Heart J Date: 2011-03 Impact factor: 4.749
Authors: Marc Cohen; Gian Franco Gensini; Frans Maritz; Enrique P Gurfinkel; Kurt Huber; Ari Timerman; Maria Krzeminska-Pakula; Jose Santopinto; Carole Hecquet; Luc Vittori Journal: Circulation Date: 2003-10-21 Impact factor: 29.690
Authors: Judith S Hochman; Harmony R Reynolds; Vladimír Dzavík; Christopher E Buller; Witold Ruzyllo; Zygmunt P Sadowski; Aldo P Maggioni; Antonio C Carvalho; James M Rankin; Harvey D White; Suzanne Goldberg; Sandra A Forman; Daniel B Mark; Gervasio A Lamas Journal: Circulation Date: 2011-10-24 Impact factor: 29.690
Authors: Venu Menon; Witold Ruzyllo; Antonio C Carvalho; Jose Marconi Almeida de Sousa; Sandra A Forman; Krystyna Jaworska; Gervasio A Lamas; Marek Roik; Christophe Thuaire; Yoav Turgeman; Judith S Hochman Journal: Am J Cardiol Date: 2013-01-22 Impact factor: 2.778